Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:16:25.641Z.
Calculation as of: 2026-10-06T16:16:25.641Z.
Quote observation: 2026-10-06T16:13:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0892caefd8f82b9b6348fc9a5fa5a469bdb14ad1115ffcc50d65bebd568510ae
PEG RATIO
N/A
Journey Medical Corporation
Market Cap
$178.44M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Journey Medical Corporation (DERM) | $178.44M | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.12M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.36M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $173.98M | N/A |
| Nkarta, Inc. (NKTX)vs › | $173.50M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $173.79M | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $186.25M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $186.92M | N/A |
| MediWound Ltd. (MDWD)vs › | $171.62M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
